The STARS (Stereotactic Radiosurgery vs. Surgery) trial will compare the three-year survival rate of patients who undergo a lobectomy, a surgical procedure to remove the tumor, versus CyberKnife treatment, a unique stereotactic body radiotherapy technique that precisely tracks and focuses the radiation on the tumor.

"Surgery is the current gold standard treatment for Stage I NSCLC. However, there are research reports that describe similar survival rates of operable patients treated with the CyberKnife," said John Dombrowski, M.D., Ph.D., assistant professor of radiation oncology at Saint Louis University School of Medicine.

Read More...